Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

The present invention provides compounds of formula (I), and pharmaceutical compositions thereof. ##STR00001##

The present invention provides compounds of formula (I), and pharmaceutical compositions thereof. ##STR00001##

The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.

##STR00001##

The invention provides compounds of formula (I):

##STR00001##

wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.

The invention provides compounds of formula (I):

##STR00001##

wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.

A process for preparing a diazabicyclooctane compound represented by the following formula (I): ##STR00001##
wherein A represents RcO; B represents NH or NC.sub.1-6 alkyl; C represents a benzyl group; Rc represents a C.sub.1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): ##STR00002##
wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

The present invention relates to a 1-phenylpropanone compound of formula (I), wherein X is CH.sub.2 or an atom selected from the group consisting of O, S and Se, n is an integer from 4 to 6, A is a substituent selected from the group consisting of 4-morpholyl, 1-piperidinyl, 4-methyl-1-piperazinyl, A being optionally substituted with a (C.sub.1-C.sub.3)alkyl or (C.sub.1-C.sub.3)acyl substituent, with the proviso that when X is CH.sub.2, n is equal to 5, for use as an antitumoral agent in the treatment of breast cancer, chronic lymphatic leukemia or neuroblastoma. The invention also concerns new 1-phenylpropanone compounds, and compounds as antitumoral agents.

##STR00001##

The present invention relates to a 1-phenylpropanone compound of formula (I), wherein X is CH.sub.2 or an atom selected from the group consisting of O, S and Se, n is an integer from 4 to 6, A is a substituent selected from the group consisting of 4-morpholyl, 1-piperidinyl, 4-methyl-1-piperazinyl, A being optionally substituted with a (C.sub.1-C.sub.3)alkyl or (C.sub.1-C.sub.3)acyl substituent, with the proviso that when X is CH.sub.2, n is equal to 5, for use as an antitumoral agent in the treatment of breast cancer, chronic lymphatic leukemia or neuroblastoma. The invention also concerns new 1-phenylpropanone compounds, and compounds as antitumoral agents.

##STR00001##